Answers are grounded in this paper and cite their sources.
In lung cancer, molecular testing and next-generation sequencing (NGS) are needed to identify therapeutic targets and are increasingly being used in earlier stages of the disease. Despite its longstanding use, it remains unclear whether transbronchial needle aspiration (TBNA) of peripheral lung lesions provides as adequate material for genetic testing as transbronchial forceps biopsies (TBFBs). In this study, we aim to analyze the use of TBNA using median viable cell area (MVCA) as a surrogate parameter to analyze sample quality.
No takes yet. Share an insight, caveat, or question.
Sticht et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: